Humacyte’s (HUMA) Buy Rating Reiterated at Benchmark

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by investment analysts at Benchmark in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other equities research analysts have also recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

HUMA opened at $3.40 on Thursday. The business’s 50-day simple moving average is $4.36 and its 200 day simple moving average is $4.96. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97. The firm has a market capitalization of $427.92 million, a PE ratio of -2.54 and a beta of 1.30.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Vanguard Group Inc. lifted its stake in shares of Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after buying an additional 543,995 shares during the last quarter. State Street Corp raised its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the period. Woodline Partners LP lifted its position in Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Humacyte by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock valued at $10,785,000 after purchasing an additional 94,915 shares during the last quarter. Finally, CenterBook Partners LP acquired a new position in shares of Humacyte in the fourth quarter valued at approximately $6,463,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.